Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2013 Feb 9

PMID 23392570

Citations 26

Authors

Leena Hilakivi-Clarke

Sonia de Assis

Anni Warri

Affiliations

Soon will be listed here.

Abstract

Women are using estrogens for many purposes, such as to prevent pregnancy or miscarriage, or to treat menopausal symptoms. Estrogens also have been used to treat breast cancer which seems puzzling, since there is convincing evidence to support a link between high lifetime estrogen exposure and increased breast cancer risk. In this review, we discuss the findings that maternal exposure to the synthetic estrogen diethylstilbestrol during pregnancy increases breast cancer risk in both exposed mothers and their daughters. In addition, we review data regarding the use of estrogens in oral contraceptives and as postmenopausal hormone therapy and discuss the opposing effects on breast cancer risk based upon timing of exposure. We place particular emphasis on studies investigating how maternal estrogenic exposures during pregnancy increase breast cancer risk among daughters. New data suggest that these exposures induce epigenetic modifications in the mammary gland and germ cells, thereby causing an inheritable increase in breast cancer risk for multiple generations.

Citing Articles

Exploring the handedness-breast cancer nexus: a comprehensive analysis via systematic review, meta-analysis, and Mendelian randomization.

Oh C, Kim E, Kim K, Oh H, Yoon J, Goh T Ther Adv Med Oncol. 2024; 16:17588359241305096.

PMID: 39669193 PMC: 11635856. DOI: 10.1177/17588359241305096.

Identification of Estrogen-Responsive Proteins in Mouse Seminal Vesicles Through Mass Spectrometry-Based Proteomics.

Kapic A, Zaman K, Nguyen V, Prokai-Tatrai K, Prokai L Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598420 PMC: 11597337. DOI: 10.3390/ph17111508.

Sonification of Deproteinized Bovine Bone Functionalized with Genistein Enhances Bone Repair in Peri-Implant Bone Defects in Ovariectomized Rats.

Duarte N, Mulinari-Santos G, de Souza Batista F, Gomes M, Monteiro N, Ervolino da Silva A J Funct Biomater. 2024; 15(11).

PMID: 39590532 PMC: 11595652. DOI: 10.3390/jfb15110328.

Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus-Faced Manner.

Suba Z Curr Oncol. 2024; 31(9):4885-4907.

PMID: 39329990 PMC: 11431267. DOI: 10.3390/curroncol31090362.

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.

Suba Z Cancers (Basel). 2024; 16(8).

PMID: 38672654 PMC: 11049279. DOI: 10.3390/cancers16081573.

References

Tomooka Y, Bern H . Growth of mouse mammary glands after neonatal sex hormone treatment. J Natl Cancer Inst. 1982; 69(6):1347-52. View

Heiss G, Wallace R, Anderson G, Aragaki A, Beresford S, Brzyski R . Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299(9):1036-45. DOI: 10.1001/jama.299.9.1036. View

Hersh A, Stefanick M, Stafford R . National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53. DOI: 10.1001/jama.291.1.47. View

Martin L, Minkin S, Boyd N . Hormone therapy, mammographic density, and breast cancer risk. Maturitas. 2009; 64(1):20-6. DOI: 10.1016/j.maturitas.2009.07.009. View

Bern H, Edery M, Mills K, Kohrman A, Mori T, Larson L . Long-term alterations in histology and steroid receptor levels of the genital tract and mammary gland following neonatal exposure of female BALB/cCrgl mice to various doses of diethylstilbestrol. Cancer Res. 1987; 47(15):4165-72. View

Umekita Y, Souda M, Hatanaka K, Hamada T, Yoshioka T, Kawaguchi H . Gene expression profile of terminal end buds in rat mammary glands exposed to diethylstilbestrol in neonatal period. Toxicol Lett. 2011; 205(1):15-25. DOI: 10.1016/j.toxlet.2011.04.031. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Marchbanks P, Curtis K, Mandel M, Wilson H, Jeng G, Folger S . Oral contraceptive formulation and risk of breast cancer. Contraception. 2011; 85(4):342-50. PMC: 3790909. DOI: 10.1016/j.contraception.2011.08.007. View

Orgeas C, Hall P, Rosenberg L, Czene K . The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. Breast Cancer Res. 2008; 10(6):R107. PMC: 2656904. DOI: 10.1186/bcr2212. View

10.

Jones L, Bern H . Long-term effects of neonatal treatment with progesterone, alone and in combination with estrogen, on the mammary gland and reproductive tract of female BALB/cfC3H mice. Cancer Res. 1977; 37(1):67-75. View

11.

Easwaran H, Johnstone S, Van Neste L, Ohm J, Mosbruger T, Wang Q . A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012; 22(5):837-49. PMC: 3337430. DOI: 10.1101/gr.131169.111. View

12.

Ravdin P, Cronin K, Howlader N, Berg C, Chlebowski R, Feuer E . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356(16):1670-4. DOI: 10.1056/NEJMsr070105. View

13.

Avril-Sassen S, Goldstein L, Stingl J, Blenkiron C, Le Quesne J, Spiteri I . Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics. 2009; 10:548. PMC: 2784809. DOI: 10.1186/1471-2164-10-548. View

14.

Sinkevicius K, Burdette J, Woloszyn K, Hewitt S, Hamilton K, Sugg S . An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008; 149(6):2970-9. PMC: 2408815. DOI: 10.1210/en.2007-1526. View

15.

Boyd N, Martin L, Yaffe M, Minkin S . Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011; 13(6):223. PMC: 3326547. DOI: 10.1186/bcr2942. View

16.

Dorgan J, Reichman M, Judd J, Brown C, Longcope C, Schatzkin A . The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States). Cancer Causes Control. 1995; 6(1):3-8. DOI: 10.1007/BF00051674. View

17.

Maruyama R, Choudhury S, Kowalczyk A, Bessarabova M, Beresford-Smith B, Conway T . Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet. 2011; 7(4):e1001369. PMC: 3080862. DOI: 10.1371/journal.pgen.1001369. View

18.

Tang W, Newbold R, Mardilovich K, Jefferson W, Cheng R, Medvedovic M . Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology. 2008; 149(12):5922-31. PMC: 2613067. DOI: 10.1210/en.2008-0682. View

19.

Shajahan A, Goel S, de Assis S, Yu B, Clarke R, Hilakivi-Clarke L . Changes in mammary caveolin-1 signaling pathways are associated with breast cancer risk in rats exposed to estradiol in utero or during prepuberty. Horm Mol Biol Clin Investig. 2013; 2(2):227-234. PMC: 3690959. DOI: 10.1515/hmbci.2010.031. View

20.

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View